Latest news with #Genmab
Yahoo
3 days ago
- Business
- Yahoo
Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Genmab A/S stands eighth on our list and has recently opened new sites in the US. Genmab A/S (NASDAQ:GMAB), a Danish biotech company founded in 1999, specializes in antibody-based therapies for cancer and serious diseases. Known for its technologies like HuMab-Mouse and UniBody, the corporation has historically partnered with major pharmaceutical companies such as Johnson & Johnson and AbbVie to bring its innovations to market. However, the company is now undergoing a strategic transformation to become a fully integrated global commercial entity. In June 2025, Genmab A/S (NASDAQ:GMAB) opened a major new U.S. site in Plainsboro, New Jersey, signaling a shift from a partnership-driven model to direct commercialization of its therapies. This move gives the company greater control over its innovation, regulatory processes, and patient outreach, aligning with a broader biotech industry trend toward independence and vertical integration. The business's oncology portfolio continues to gain traction. Tivdak (cervical cancer) received full FDA approval in April 2024, while Epkinly (lymphoma), which earned accelerated approval in 2023, has shown strong sales growth in the U.S. Genmab A/S (NASDAQ:GMAB)'s pipeline also remains active, with ongoing development of therapies like Epcoritamab and Acasunlimab. At the June 2025 ASCO meeting, the company presented promising Rina-S data, supporting an upcoming Phase III trial. A healthcare professional wearing a health communications device discussing patient data with a colleague. The corporation continues to benefit from its successful collaboration with Johnson & Johnson on DARZALEX, which remains a significant revenue driver. The company is also focused on long-term growth by investing in talent retention through stock-based incentives. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
4 days ago
- Business
- Yahoo
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
Genmab A/S (NASDAQ:GMAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 8, Truist Securities reiterated a 'Buy' rating on the stock and increased its price target to $46 from $45. A doctor in a hospital consulting with a cancer patient about immuno-oncology therapy. According to Truist Securities, the current valuation does not depict the company's fair value. That's because it boasts an established revenue and solid pipeline potential. The price target adjustment underscores Truist Securities' confidence about Genmab's revenue outlook for 2025. The research firm is confident about the company's cancer drug Darzalex as prescription data indicates 10% quarter-over-quarter growth in Q2. The firm is also bullish about the company's other products, including Epkinly and Kesimpta. Truist Securities has also expressed confidence in Genmab's pipeline assets, including Rina-S, Acasun, and Gen1042, which it believes are undervalued. Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. It utilizes advanced antibody technologies, such as DuoBody and HexaBody, to create next-generation therapeutic antibodies. While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
16-07-2025
- Business
- Yahoo
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX ® in the U.S.), as reported by J&J were USD 3,539 million in the second quarter of 2025. Net trade sales were USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E: mmp@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ This Company Announcement contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson & Johnson. Company Announcement no. 38CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark Attachment 160725_CA38_DARZALEX Q2 2025 salesError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
09-07-2025
- Business
- Globe and Mail
Refractory Metastatic Melanoma Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Refractory Metastatic Melanoma Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Refractory Metastatic Melanoma Research. Learn more about our innovative pipeline today! @ Refractory Metastatic Melanoma Pipeline Outlook Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report In July 2025, Genmab announced clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo. DelveInsight's Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Refractory Metastatic Melanoma treatment. The leading Refractory Metastatic Melanoma Companies such as BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Promising Refractory Metastatic Melanoma Pipeline Therapies such as GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others. Stay informed about the cutting-edge advancements in Refractory Metastatic Melanoma treatments. Download for updates and be a part of the revolution in Dermatology care @ Refractory Metastatic Melanoma Clinical Trials Assessment Refractory Metastatic Melanoma Emerging Drugs Profile BNT111: BioNTech SE BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory/relapsed, unresectable Stage III or IV melanoma. BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as uridine mRNA-lipoplex formulation. Over 90% of patients with cutaneous melanomas express at least one of these antigens. The BNT111 program has also received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration. Currently, the drug is in Phase II stage of its development for the treatment of Refractory Metastatic Melanoma. GD2-SADA: Y-mAbs Therapeutics The GD2-SADA construct is created using SADA technology, that utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs attached to the tumor target in order to radiate the tumor. This provides the possibility of targeting tumors with precision while minimizing radiation of normal tissues. The SADA technology platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for theragnostic purposes. Currently, the drug is in Phase I stage of its development for the treatment of Refractory Metastatic Melanoma. The Refractory Metastatic Melanoma Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Metastatic Melanoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Metastatic Melanoma Treatment. Refractory Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Refractory Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Metastatic Melanoma market. Learn more about Refractory Metastatic Melanoma Drugs opportunities in our groundbreaking Refractory Metastatic Melanoma research and development projects @ Refractory Metastatic Melanoma Unmet Needs Refractory Metastatic Melanoma Companies BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Refractory Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Refractory Metastatic Melanoma treatment by visiting our website. Stay informed about how we're transforming the future of dermatology @ Refractory Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives Scope of the Refractory Metastatic Melanoma Pipeline Report Coverage- Global Refractory Metastatic Melanoma Companies- BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Refractory Metastatic Melanoma Pipeline Therapies- GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others. Refractory Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Refractory Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Refractory Metastatic Melanoma Pipeline on our website @ Refractory Metastatic Melanoma Emerging Drugs and Companies Table of Contents Introduction Executive Summary Refractory Metastatic Melanoma: Overview Pipeline Therapeutics Therapeutic Assessment Refractory Metastatic Melanoma – DelveInsight's Analytical Perspective In-depth Commercial Assessment Refractory Metastatic Melanoma Collaboration Deals Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) BNT111: BioNTech SE Drug profiles in the detailed report….. Early Stage Products (Phase I) GD2-SADA: Y-mAbs Therapeutics Drug profiles in the detailed report… Pre-clinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Refractory Metastatic Melanoma Key Companies Refractory Metastatic Melanoma Key Products Refractory Metastatic Melanoma- Unmet Needs Refractory Metastatic Melanoma- Market Drivers and Barriers Refractory Metastatic Melanoma- Future Perspectives and Conclusion Refractory Metastatic Melanoma Analyst Views Refractory Metastatic Melanoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
03-07-2025
- Business
- Yahoo
M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates
-- Morgan Stanley has begun coverage of Genmab (CSE:GMAB) (NASDAQ:GMAB) with an Equal-Weight rating and a price objective of $24, reduced slightly from the previous $25 target. The Wall Street bank sees limited near-term upside as the most impactful catalysts are expected in 2026. 'Given that particular catalysts poised to most likely re-rate GMAB stock are anticipated to occur in 2026, we assume coverage at EW rating and look toward incremental updates on development timelines and commercial execution over the remainder of 2025,' analyst Judah C. Frommer said. Genmab is navigating a transition away from heavy reliance on Darzalex royalties and focusing more on its proprietary pipeline, particularly Epkinly, Rina-S, and acasunlimab. Following Johnson & Johnson (NYSE:JNJ)'s decision not to opt into the HexaBody-CD38 program, Frommer says attention will shift to maximizing internal pipeline value. For Epkinly, a supplemental BLA has been submitted in 2L+ follicular lymphoma based on the EPCORE-FL-1 study. While top-line data showed the study met one of its co-primary endpoints, progression-free survival data are still pending and expected later this year. More significant Phase III readouts for Epkinly in earlier-line DLBCL are scheduled for 2026. 'In the near-term however, focus remains on current commercial execution strategy in the 3L+ settings for DLBCL and FL as we await key data updates,' Frommer added. Meanwhile, Rina-S is progressing across multiple indications. At American Society of Clinical Oncology (ASCO), data in endometrial cancer showed response rates of 50% and 47% in two dose cohorts. The company plans to initiate a pivotal Phase III trial in 2L+ endometrial cancer in the second half of 2025 and a separate trial in platinum-sensitive ovarian cancer before year-end. Acasunlimab also remains a focus. Morgan Stanley expects updated Phase II data in 2L+ NSCLC later this year. The Phase III trial, which uses overall survival as the primary endpoint, is anticipated to read out in 2027. In sum, though Morgan Stanley views Genmab's management execution and pipeline-building strategy as sound, it sees 2026 as a more realistic timeframe for material stock re-rating. In the meantime, 'we look toward updates on development timelines and commercial execution over the remainder of 2025,' the bank said. Related articles takes neutral stance on Genmab ahead of portfolio, execution updates MS initiates coverage on AI Biotechs, flags key pipeline catalysts Chip stock targets raised at Mizuho following recent rally Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
